Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

The news came as RBC Capital analyst Luca Issi initiated coverage on Argenx with an outperform rating and 850 price target, saying that doctor checks point to accelerating uptake of Vyvgart, according ...

Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: ...

While counties are required to set aside at least 30 percent of their budgets to development projects, CoB documents also ...

Step up in your career with a world-class executive MBA program crafted for mid to senior executives. Enrol today and lead with confidence.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

As biotech firm Sarepta Therapeutics (NASD: SRPT) battles patient deaths, regulatory action, and a cratering stock price, its dealings with the Food and Drug Administration are being monitored closely ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

As global markets react to U.S. inflation data and the potential for Federal Reserve rate cuts, small-cap stocks have surged, with the Russell 2000 Index notably outperforming larger indices like the ...

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...

Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.